Sex: U
Vaccine: COVID19
Symptoms: COVID-19, Progressive multiple sclerosis
Clinical narrative: has MS and got Covid a year ago in Aug2022 / clarified that MS is Multiple Sclerosis/ progressive multiple sclerosis; Had covid at the end of Aug2022; This spontaneous case was reported by a patient and describes the occurrence of PROGRESSIVE MULTIPLE SCLEROSIS (has MS and got Covid a year ago in Aug2022 / clarified that MS is Multiple Sclerosis/ progressive multiple sclerosis) in a patient of an unknown age and gender who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Multiple sclerosis (Patient had a spinal tap to prove had MS. Patient Thinks it was in 2012.).    On an unknown date, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (unknown route) 1 dosage form. In August 2022, the patient experienced COVID-19 (Had covid at the end of Aug2022). On an unknown date, the patient experienced PROGRESSIVE MULTIPLE SCLEROSIS (has MS and got Covid a year ago in Aug2022 / clarified that MS is Multiple Sclerosis/ progressive multiple sclerosis) (seriousness criterion medically significant). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) (oral use) from 26-Aug-2022 to 31-Aug-2022 for COVID-19 treatment, at a dose of took them twice a day by mouth. At the time of the report, PROGRESSIVE MULTIPLE SCLEROSIS (has MS and got Covid a year ago in Aug2022 / clarified that MS is Multiple Sclerosis/ progressive multiple sclerosis) was resolving and COVID-19 (Had covid at the end of Aug2022) had resolved.        The action taken with SPIKEVAX NOS (SPIKEVAX NOS) (Unknown) was unknown.       No concomitant medication was reported. Company comment: This is a spontaneous case concerning a patient of unknown age and gender with Multiple Sclerosis, who experienced the unexpected serious (medically significant)  AESI of Progressive multiple sclerosis and non-serious event of COVID-19. COVID-19 occurred after the administration of unknown dose of SPIKEVAX COVID-19 VACCINE NOS vaccine, latency is unknown, and was treated with Paxlovid. Patient experienced MS improvement after Paxlovid. It is unclear if the reported Progressive multiple sclerosis was before of after the administration of Spikevax. No further information was available in the report. Progressive multiple sclerosis could be explained by the natural course of the disease. The company causality for the event COVID-19 was assessed as not applicable, since SPIKEVAX COVID-19 VACCINE NOS vaccine is a nucleoside modified vaccine that does not contain any virus capable of causing viral infection. The event might be explained by current pandemic outbreak. The benefit-risk relationship of SPIKEVAX COVID-19 VACCINE NOS Vaccine is not affected by this report.  Reported that progressive multiple sclerosis No inflammation they can see but it was slowing getting worse that's why they were calling it MS. Reportedly, patient had MS (Multiple sclerosis) and got COVID a year ago in Aug-2022. Patient was prescribed Paxlovid and said that felt that the Paxlovid really helped MS. Patient was wondering if anyone else felt that way. When went in to see the doctor it was about the 05-Sep-2022. Had COVID at the end of Aug-2022 and they prescribed Paxlovid over the phone and went to her doctor about 5 days later and felt great. Her spasticity was gone. left arm was usually stayed bent and was hard to bend and it was able to be straightened out and could sleep with it completely down and had lots of energy. Her spasticity had come back though. Said that her symptoms lasted about a week or 2 after her last dose of Paxlovid. Clarified that saw the doctor on 06-Sep-2022.; Sender's Comments: This is a spontaneous case concerning a patient of unknown age and gender with Multiple Sclerosis, who experienced the unexpected serious (medically significant)  AESI of Progressive multiple sclerosis and non-serious event of COVID-19. COVID-19 occurred after the administration of unknown dose of SPIKEVAX COVID-19 VACCINE NOS vaccine, latency is unknown, and was treated with Paxlovid. Patient experienced MS improvement after Paxlovid. It is unclear if the reported Progressive multiple sclerosis was before of after the administration of Spikevax. No further information was available in the report. Progressive multiple sclerosis could be explained by the natural course of the disease. The company causality for the event COVID-19 was assessed as not applicable, since SPIKEVAX COVID-19 VACCINE NOS vaccine is a nucleoside modified vaccine that does not contain any virus capable of causing viral infection. The event might be explained by current pandemic outbreak. The benefit-risk relationship of SPIKEVAX COVID-19 VACCINE NOS Vaccine is not affected by this report.